Figure 6.

SchB restrains the growth and CSC characteristics of NCI-H460-CSCs in vivo. Nude mice were divided into three groups: Control, 400 mg/kg SchB and 800 mg/kg SchB groups. After subcutaneous injection with NCI-H460-CSCs, mice in the SchB-treated groups were administrated with 400 or 800 mg/kg SchB by oral gavage and mice treated with PBS were used as a negative control. (A) Size and (B) weight of neoplasms isolated from mice in different groups. (C) Hematoxylin and eosin, and immunohistochemical analyses for proliferating cell nuclear antigen in tumor tissues. Scale bar, 100 µm. Western blotting was conducted to estimate the impact of SchB on (D) EMT, (E) stemness and (F) NF-κB and p38 MAPK signaling pathways. All experimental data are shown as the mean ± SD (n=10). Differences were analyzed by one-way ANOVA with Tukey's correction. **P<0.01 vs. control. SchB, Schisandrin B; CSC, cancer stem cell; Oct-4, octamer-binding transcription factor 4; Bmi-1, B lymphoma Mo-MLV insertion region 1 homolog; IκBα, inhibitor of nuclear factor κB α; p, phosphorylated.